Why the study?
Although patients with end-stage renal disease face a high risk of sudden cardiac death, the benefits of implantable cardioverter-defibrillator therapy in this population remain controversial due to conflicting study results.
Does implantable cardioverter-defibrillator therapy prevent sudden cardiac death in end-stage renal disease patients on dialysis?
Population
Patients with end-stage renal disease on dialysis and chronic kidney disease
Design
Review
Authors
Loading...
ICDs in ESRD dialysis patients warrant individualized risk assessment amid uncertainties; leaves open definitive efficacy data from prospective trials.
Does implantable cardioverter-defibrillator therapy prevent sudden cardiac death in end-stage renal disease patients on dialysis?
The use of ICDs in ESRD patients on dialysis remains controversial due to conflicting efficacy data and significant periprocedural risks, requiring careful consideration of life expectancy and individual risk.
Franczyk et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: